257 related articles for article (PubMed ID: 33852832)
1. A Fc engineering approach to define functional humoral correlates of immunity against Ebola virus.
Gunn BM; Lu R; Slein MD; Ilinykh PA; Huang K; Atyeo C; Schendel SL; Kim J; Cain C; Roy V; Suscovich TJ; Takada A; Halfmann PJ; Kawaoka Y; Pauthner MG; Momoh M; Goba A; Kanneh L; Andersen KG; Schieffelin JS; Grant D; Garry RF; Saphire EO; Bukreyev A; Alter G
Immunity; 2021 Apr; 54(4):815-828.e5. PubMed ID: 33852832
[TBL] [Abstract][Full Text] [Related]
2. A Role for Fc Function in Therapeutic Monoclonal Antibody-Mediated Protection against Ebola Virus.
Gunn BM; Yu WH; Karim MM; Brannan JM; Herbert AS; Wec AZ; Halfmann PJ; Fusco ML; Schendel SL; Gangavarapu K; Krause T; Qiu X; He S; Das J; Suscovich TJ; Lai J; Chandran K; Zeitlin L; Crowe JE; Lauffenburger D; Kawaoka Y; Kobinger GP; Andersen KG; Dye JM; Saphire EO; Alter G
Cell Host Microbe; 2018 Aug; 24(2):221-233.e5. PubMed ID: 30092199
[TBL] [Abstract][Full Text] [Related]
3. Associations Between Antibody Fc-Mediated Effector Functions and Long-Term Sequelae in Ebola Virus Survivors.
Paquin-Proulx D; Gunn BM; Alrubayyi A; Clark DV; Creegan M; Kim D; Kibuuka H; Millard M; Wakabi S; Eller LA; Michael NL; Schoepp RJ; Hepburn MJ; Hensley LE; Robb ML; Alter G; Eller MA
Front Immunol; 2021; 12():682120. PubMed ID: 34093585
[TBL] [Abstract][Full Text] [Related]
4. Differential requirements for FcγR engagement by protective antibodies against Ebola virus.
Bournazos S; DiLillo DJ; Goff AJ; Glass PJ; Ravetch JV
Proc Natl Acad Sci U S A; 2019 Oct; 116(40):20054-20062. PubMed ID: 31484758
[TBL] [Abstract][Full Text] [Related]
5. Fc-Mediated Antibody Effector Functions During Respiratory Syncytial Virus Infection and Disease.
van Erp EA; Luytjes W; Ferwerda G; van Kasteren PB
Front Immunol; 2019; 10():548. PubMed ID: 30967872
[TBL] [Abstract][Full Text] [Related]
6. Extra-Neutralizing FcR-Mediated Antibody Functions for a Universal Influenza Vaccine.
Boudreau CM; Alter G
Front Immunol; 2019; 10():440. PubMed ID: 30949165
[TBL] [Abstract][Full Text] [Related]
7. Cell-targeting antibodies in immunity to Ebola.
Schmaljohn A; Lewis GK
Pathog Dis; 2016 Jun; 74(4):ftw021. PubMed ID: 27005312
[TBL] [Abstract][Full Text] [Related]
8. Analysis of a Therapeutic Antibody Cocktail Reveals Determinants for Cooperative and Broad Ebolavirus Neutralization.
Gilchuk P; Murin CD; Milligan JC; Cross RW; Mire CE; Ilinykh PA; Huang K; Kuzmina N; Altman PX; Hui S; Gunn BM; Bryan AL; Davidson E; Doranz BJ; Turner HL; Alkutkar T; Flinko R; Orlandi C; Carnahan R; Nargi R; Bombardi RG; Vodzak ME; Li S; Okoli A; Ibeawuchi M; Ohiaeri B; Lewis GK; Alter G; Bukreyev A; Saphire EO; Geisbert TW; Ward AB; Crowe JE
Immunity; 2020 Feb; 52(2):388-403.e12. PubMed ID: 32023489
[TBL] [Abstract][Full Text] [Related]
9. Multifunctional Pan-ebolavirus Antibody Recognizes a Site of Broad Vulnerability on the Ebolavirus Glycoprotein.
Gilchuk P; Kuzmina N; Ilinykh PA; Huang K; Gunn BM; Bryan A; Davidson E; Doranz BJ; Turner HL; Fusco ML; Bramble MS; Hoff NA; Binshtein E; Kose N; Flyak AI; Flinko R; Orlandi C; Carnahan R; Parrish EH; Sevy AM; Bombardi RG; Singh PK; Mukadi P; Muyembe-Tamfum JJ; Ohi MD; Saphire EO; Lewis GK; Alter G; Ward AB; Rimoin AW; Bukreyev A; Crowe JE
Immunity; 2018 Aug; 49(2):363-374.e10. PubMed ID: 30029854
[TBL] [Abstract][Full Text] [Related]
10. Ebola virus glycoprotein Fc fusion protein confers protection against lethal challenge in vaccinated mice.
Konduru K; Bradfute SB; Jacques J; Manangeeswaran M; Nakamura S; Morshed S; Wood SC; Bavari S; Kaplan GG
Vaccine; 2011 Apr; 29(16):2968-77. PubMed ID: 21329775
[TBL] [Abstract][Full Text] [Related]
11. Ebolavirus Glycoprotein Fc Fusion Protein Protects Guinea Pigs against Lethal Challenge.
Konduru K; Shurtleff AC; Bradfute SB; Nakamura S; Bavari S; Kaplan G
PLoS One; 2016; 11(9):e0162446. PubMed ID: 27622456
[TBL] [Abstract][Full Text] [Related]
12. Development of a Human Antibody Cocktail that Deploys Multiple Functions to Confer Pan-Ebolavirus Protection.
Wec AZ; Bornholdt ZA; He S; Herbert AS; Goodwin E; Wirchnianski AS; Gunn BM; Zhang Z; Zhu W; Liu G; Abelson DM; Moyer CL; Jangra RK; James RM; Bakken RR; Bohorova N; Bohorov O; Kim DH; Pauly MH; Velasco J; Bortz RH; Whaley KJ; Goldstein T; Anthony SJ; Alter G; Walker LM; Dye JM; Zeitlin L; Qiu X; Chandran K
Cell Host Microbe; 2019 Jan; 25(1):39-48.e5. PubMed ID: 30629917
[TBL] [Abstract][Full Text] [Related]
13. Optimization of Prime-Boost Vaccination Strategies Against Mouse-Adapted Ebolavirus in a Short-Term Protection Study.
Aviles J; Bello A; Wong G; Fausther-Bovendo H; Qiu X; Kobinger G
J Infect Dis; 2015 Oct; 212 Suppl 2():S389-97. PubMed ID: 26038398
[TBL] [Abstract][Full Text] [Related]
14. Distinct Immunogenicity and Efficacy of Poxvirus-Based Vaccine Candidates against Ebola Virus Expressing GP and VP40 Proteins.
Lázaro-Frías A; Gómez-Medina S; Sánchez-Sampedro L; Ljungberg K; Ustav M; Liljeström P; Muñoz-Fontela C; Esteban M; García-Arriaza J
J Virol; 2018 Jun; 92(11):. PubMed ID: 29514907
[No Abstract] [Full Text] [Related]
15. Antibody-mediated protection against Ebola virus.
Saphire EO; Schendel SL; Gunn BM; Milligan JC; Alter G
Nat Immunol; 2018 Nov; 19(11):1169-1178. PubMed ID: 30333617
[TBL] [Abstract][Full Text] [Related]
16. A novel Ebola virus antibody-dependent cell-mediated cytotoxicity (Ebola ADCC) assay.
Singh K; Marasini B; Chen X; Spearman P
J Immunol Methods; 2018 Sep; 460():10-16. PubMed ID: 29894746
[TBL] [Abstract][Full Text] [Related]
17. Antibody-Dependent Enhancement of Ebola Virus Infection by Human Antibodies Isolated from Survivors.
Kuzmina NA; Younan P; Gilchuk P; Santos RI; Flyak AI; Ilinykh PA; Huang K; Lubaki NM; Ramanathan P; Crowe JE; Bukreyev A
Cell Rep; 2018 Aug; 24(7):1802-1815.e5. PubMed ID: 30110637
[TBL] [Abstract][Full Text] [Related]
18. In Vitro Characterization and In Vivo Effectiveness of Ebola Virus Specific Equine Polyclonal F(ab')2.
Racine T; Denizot M; Pannetier D; Nguyen L; Pasquier A; Raoul H; Saluzzo JF; Kobinger G; Veas F; Herbreteau CH
J Infect Dis; 2019 Jun; 220(1):41-45. PubMed ID: 30852585
[TBL] [Abstract][Full Text] [Related]
19. Multiple viral proteins and immune response pathways act to generate robust long-term immunity in Sudan virus survivors.
Sobarzo A; Stonier SW; Radinsky O; Gelkop S; Kuehne AI; Edri A; Herbert AS; Fedida-Metula S; Lutwama JJ; Yavelsky V; Davis C; Porgador A; Dye JM; Lobel L
EBioMedicine; 2019 Aug; 46():215-226. PubMed ID: 31326432
[TBL] [Abstract][Full Text] [Related]
20. Longitudinal Human Antibody Repertoire against Complete Viral Proteome from Ebola Virus Survivor Reveals Protective Sites for Vaccine Design.
Khurana S; Ravichandran S; Hahn M; Coyle EM; Stonier SW; Zak SE; Kindrachuk J; Davey RT; Dye JM; Chertow DS
Cell Host Microbe; 2020 Feb; 27(2):262-276.e4. PubMed ID: 32053790
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
